Shuxia Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shuxia Wang has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Yanzhang Li
Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky, USA
10 shared publicationsHasiyeti Maimaitiyiming
Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky, United States of America
8 shared publicationsHeather Norman
Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40536, USA; Lexington Veterans Affairs Medical Center, Lexington, KY, USA
7 shared publicationsQi Zhou
Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, USA
7 shared publicationsTaesik Gwag
Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, USA
5 shared publicationsWenpeng Cui
Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY 40536, USA; Department of Nephrology, Second Hospital of Jilin University, Changchun 130041, China
5 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by Impact Journals, LLC in Aging
- Vol. 17 (12) , 2884-2901
CD47 antisense oligonucleotide treatment improves glucose homeostasis and alleviates dyslipidemia in aged male mice
As the global elderly population grows, age-associated metabolic disorders pose increasing public health challenges, highlighting the need for effective therapies. CD47, a transmembrane protein involved in immune and metabolic regulation, has been previously implicated in aging-related metabolic dysfunction. In this study, we investigated whether targeting CD47 by antisense oligonucleotide (ASO) could improve metabolic health in aged male mice. Twenty-month-old male mice were treated with control ASO or CD47 ASO (25 μg/g) for 10 weeks. We found that CD47ASO treatment selectively reduced visceral adiposity without affecting overall body weight in aged mice. It also improved glucose tolerance, insulin sensitivity, and hyperlipidemia—key metabolic disturbances commonly associated with aging. Mechanistically, CD47 ASO treatment reduced adipocyte size in visceral fat by suppressing lipogenesis rather than enhancing lipolysis, which was confirmed in vitro 3T3-L1 adipocyte model. It also stimulated hepatic glucose metabolism and improved brown adipose tissue (BAT) function by upregulating the expression of genes related to thermogenesis and endocrine signaling, including UCP1, CPT1β, and Neuregulin 4 (NRG4). Together, these findings support a beneficial role for CD47 knockdown in alleviating age-associated metabolic dysfunction through coordinated effects across multiple organs.
- 1 December 2025
- Published by Impact Journals, LLC in Aging
- Vol. 17 (12) , 2884-2901
Open AccessCD47 antisense oligonucleotide treatment improves glucose homeostasis and alleviates dyslipidemia in aged male mice
As the global elderly population grows, age-associated metabolic disorders pose increasing public health challenges, highlighting the need for effective therapies. CD47, a transmembrane protein involved in immune and metabolic regulation, has been previously implicated in aging-related metabolic dysfunction. In this study, we investigated whether targeting CD47 by antisense oligonucleotide (ASO) could improve metabolic health in aged male mice. Twenty-month-old male mice were treated with control ASO or CD47 ASO (25 μg/g) for 10 weeks. We found that CD47ASO treatment selectively reduced visceral adiposity without affecting overall body weight in aged mice. It also improved glucose tolerance, insulin sensitivity, and hyperlipidemia—key metabolic disturbances commonly associated with aging. Mechanistically, CD47 ASO treatment reduced adipocyte size in visceral fat by suppressing lipogenesis rather than enhancing lipolysis, which was confirmed in vitro 3T3-L1 adipocyte model. It also stimulated hepatic glucose metabolism and improved brown adipose tissue (BAT) function by upregulating the expression of genes related to thermogenesis and endocrine signaling, including UCP1, CPT1β, and Neuregulin 4 (NRG4). Together, these findings support a beneficial role for CD47 knockdown in alleviating age-associated metabolic dysfunction through coordinated effects across multiple organs.
- Open Access
- 13 October 2025
- Published by BMJ in eGastroenterology
- Vol. 3 (4) , e100242
CD47: an immunoregulatory nexus in liver and gastrointestinal disorders
Cluster of differentiation 47 (CD47) is a widely expressed transmembrane protein that serves as a critical immunoregulatory checkpoint in both homeostatic and pathological conditions of the digestive system. It interacts with signal regulatory protein alpha to send a ‘do not eat me’ signal, thereby preventing phagocytosis and shaping immune responses. Beyond immunity, CD47 also influences cell death, growth and metabolism through interactions with integrins and thrombospondin-1. Recent studies implicate CD47 as a central nexus in the pathogenesis of diverse liver and gastrointestinal disorders, including metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction-associated steatohepatitis, inflammatory bowel disease, liver ischaemia-reperfusion injury, drug-induced liver injury and gastrointestinal malignancies such as hepatocellular carcinoma, colorectal and pancreatic cancers. CD47 contributes to disease progression through immune modulation, endothelial dysfunction, fibrogenic activation and suppression of antitumour immunity. This review summarises current mechanistic insights into CD47 signalling across digestive diseases and highlights its emerging potential as a therapeutic target for immunometabolic and oncological interventions in gastroenterology and hepatology.
- 13 October 2025
- Published by BMJ in eGastroenterology
- Vol. 3 (4) , e100242
Open AccessCD47: an immunoregulatory nexus in liver and gastrointestinal disorders
Cluster of differentiation 47 (CD47) is a widely expressed transmembrane protein that serves as a critical immunoregulatory checkpoint in both homeostatic and pathological conditions of the digestive system. It interacts with signal regulatory protein alpha to send a ‘do not eat me’ signal, thereby preventing phagocytosis and shaping immune responses. Beyond immunity, CD47 also influences cell death, growth and metabolism through interactions with integrins and thrombospondin-1. Recent studies implicate CD47 as a central nexus in the pathogenesis of diverse liver and gastrointestinal disorders, including metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction-associated steatohepatitis, inflammatory bowel disease, liver ischaemia-reperfusion injury, drug-induced liver injury and gastrointestinal malignancies such as hepatocellular carcinoma, colorectal and pancreatic cancers. CD47 contributes to disease progression through immune modulation, endothelial dysfunction, fibrogenic activation and suppression of antitumour immunity. This review summarises current mechanistic insights into CD47 signalling across digestive diseases and highlights its emerging potential as a therapeutic target for immunometabolic and oncological interventions in gastroenterology and hepatology.
- Open Access
- 26 January 2024
- Published by Elsevier in JHEP Reports
- Vol. 6 (4) , 101019
Platelet-derived thrombospondin 1 promotes immune cell liver infiltration and exacerbates diet-induced steatohepatitis
- 26 January 2024
- Published by Elsevier in JHEP Reports
- Vol. 6 (4) , 101019
Open AccessPlatelet-derived thrombospondin 1 promotes immune cell liver infiltration and exacerbates diet-induced steatohepatitis
- Open Access
- 18 November 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-10
Thrombospondin1 antagonist peptide treatment attenuates obesity-associated chronic inflammation and metabolic disorders in a diet-induced obese mouse model
Thrombospondin1 (TSP1) is a multifunctional matricellular protein. Previously, we demonstrated that TSP1 plays a pivotal role in obesity-related inflammation and insulin resistance (IR) by modulating macrophage accumulation and activation in adipose tissue. Moreover, in our in vitro studies, a CD36-derived peptide, functioning as a TSP1 antagonist, effectively inhibited TSP1-induced proinflammatory macrophage activation. However, whether this CD36 peptide can inhibit obesity-induced inflammation and IR in vivo is unknown and determined in this study in a high fat diet-induced obese mouse model (DIO). CD36 peptide or control peptide was intraperitoneally administered into the established obese mice triweekly for 6 weeks. We found that CD36 peptide treatment didn’t affect obesity or weight gain but significantly reduced proinflammatory cytokine production systemically and in visceral fat tissue. Adipose tissue exhibited fewer crown-like structures and reduced macrophage infiltration. CD36 peptide treatment also attenuated the proinflammatory phenotype of bone marrow derived macrophages from obese mice. Furthermore, CD36 peptide treatment improved glucose tolerance and insulin sensitivity, and mitigated obesity-related fatty liver disease and kidney damage. Collectively, this study suggests that the CD36 peptide, as a TSP1 antagonist, shows promise as a novel therapeutic approach for managing obesity-related metabolic disorders.
- 18 November 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-10
Open AccessThrombospondin1 antagonist peptide treatment attenuates obesity-associated chronic inflammation and metabolic disorders in a diet-induced obese mouse model
Thrombospondin1 (TSP1) is a multifunctional matricellular protein. Previously, we demonstrated that TSP1 plays a pivotal role in obesity-related inflammation and insulin resistance (IR) by modulating macrophage accumulation and activation in adipose tissue. Moreover, in our in vitro studies, a CD36-derived peptide, functioning as a TSP1 antagonist, effectively inhibited TSP1-induced proinflammatory macrophage activation. However, whether this CD36 peptide can inhibit obesity-induced inflammation and IR in vivo is unknown and determined in this study in a high fat diet-induced obese mouse model (DIO). CD36 peptide or control peptide was intraperitoneally administered into the established obese mice triweekly for 6 weeks. We found that CD36 peptide treatment didn’t affect obesity or weight gain but significantly reduced proinflammatory cytokine production systemically and in visceral fat tissue. Adipose tissue exhibited fewer crown-like structures and reduced macrophage infiltration. CD36 peptide treatment also attenuated the proinflammatory phenotype of bone marrow derived macrophages from obese mice. Furthermore, CD36 peptide treatment improved glucose tolerance and insulin sensitivity, and mitigated obesity-related fatty liver disease and kidney damage. Collectively, this study suggests that the CD36 peptide, as a TSP1 antagonist, shows promise as a novel therapeutic approach for managing obesity-related metabolic disorders.
- 22 July 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 676, 78-83
Sex differences in the effects of brown adipocyte CD47 deficiency on age-related weight change and glucose homeostasis
- 22 July 2023
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 676, 78-83
Sex differences in the effects of brown adipocyte CD47 deficiency on age-related weight change and glucose homeostasis
- Open Access
- 16 February 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-10
CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
Previous study from our lab has revealed a new role of CD47 in regulating adipose tissue function, energy homeostasis and the development of obesity and metabolic disease in CD47 deficient mice. In this study, the therapeutic potential of an antisense oligonucleotide (ASO) targeting to CD47 in obesity and its-associated complications was determined in two obese mouse models (diet induced and genetic models). In diet induced obesity, male C57BL6 mice were fed with high fat (HF) diet to induce obesity and then treated with CD47ASO or control ASO for 8 weeks. In genetic obese mouse model, male six-week old ob/ob mice were treated with ASOs for 9 weeks. We found that CD47ASO treatment reduced HF diet-induced weight gain, decreased fat mass, prevented dyslipidemia, and improved glucose tolerance. These changes were accompanied by reduced inflammation in white adipose tissue and decreased hepatic steatosis. This protection was also seen in CD47ASO treated ob/ob mice. Mechanistically, CD47ASO treatment increased mice physical activity and energy expenditure, contributing to weight loss and improved metabolic outcomes in obese mice. Collectively, these findings suggest that CD47ASO might serve as a new treatment option for obesity and its-associated metabolic complications.
- 16 February 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-10
Open AccessCD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
Previous study from our lab has revealed a new role of CD47 in regulating adipose tissue function, energy homeostasis and the development of obesity and metabolic disease in CD47 deficient mice. In this study, the therapeutic potential of an antisense oligonucleotide (ASO) targeting to CD47 in obesity and its-associated complications was determined in two obese mouse models (diet induced and genetic models). In diet induced obesity, male C57BL6 mice were fed with high fat (HF) diet to induce obesity and then treated with CD47ASO or control ASO for 8 weeks. In genetic obese mouse model, male six-week old ob/ob mice were treated with ASOs for 9 weeks. We found that CD47ASO treatment reduced HF diet-induced weight gain, decreased fat mass, prevented dyslipidemia, and improved glucose tolerance. These changes were accompanied by reduced inflammation in white adipose tissue and decreased hepatic steatosis. This protection was also seen in CD47ASO treated ob/ob mice. Mechanistically, CD47ASO treatment increased mice physical activity and energy expenditure, contributing to weight loss and improved metabolic outcomes in obese mice. Collectively, these findings suggest that CD47ASO might serve as a new treatment option for obesity and its-associated metabolic complications.
- Open Access
- 13 February 2023
- Published by Springer Nature in Research Square
CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
Previous study from our lab has revealed a new role of CD47 in regulating adipose tissue function, energy homeostasis and the development of obesity and metabolic disease in CD47 deficient mice. In this study, the therapeutic potential of an antisense oligonucleotide (ASO) targeting to CD47 in obesity and its-associated complications was determined in two obese mouse models (diet induced and genetic models). In diet induced obesity, male C57BL6 mice were fed with high fat (HF) diet to induce obesity and then treated with CD47ASO or control ASO for 8 weeks. In genetic obese mouse model, male six-week old ob/ob mice were treated with ASOs for 9 weeks. We found that CD47ASO treatment reduced HF diet-induced weight gain, decreased fat mass, prevented dyslipidemia, and improved glucose tolerance. These changes were accompanied by reduced inflammation in white adipose tissue and decreased hepatic steatosis. This protection was also seen in CD47ASO treated ob/ob mice. Mechanistically, CD47ASO treatment increased mice physical activity and energy expenditure, contributing to weight loss and improved metabolic outcomes in obese mice. Collectively, these findings suggest that CD47ASO might serve as a new treatment option for obesity and its-associated metabolic complications.
- 13 February 2023
- Published by Springer Nature in Research Square
Open AccessCD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction
Previous study from our lab has revealed a new role of CD47 in regulating adipose tissue function, energy homeostasis and the development of obesity and metabolic disease in CD47 deficient mice. In this study, the therapeutic potential of an antisense oligonucleotide (ASO) targeting to CD47 in obesity and its-associated complications was determined in two obese mouse models (diet induced and genetic models). In diet induced obesity, male C57BL6 mice were fed with high fat (HF) diet to induce obesity and then treated with CD47ASO or control ASO for 8 weeks. In genetic obese mouse model, male six-week old ob/ob mice were treated with ASOs for 9 weeks. We found that CD47ASO treatment reduced HF diet-induced weight gain, decreased fat mass, prevented dyslipidemia, and improved glucose tolerance. These changes were accompanied by reduced inflammation in white adipose tissue and decreased hepatic steatosis. This protection was also seen in CD47ASO treated ob/ob mice. Mechanistically, CD47ASO treatment increased mice physical activity and energy expenditure, contributing to weight loss and improved metabolic outcomes in obese mice. Collectively, these findings suggest that CD47ASO might serve as a new treatment option for obesity and its-associated metabolic complications.
- 15 February 2022
- Published by Wiley in Liver International
- Vol. 42 (4) , 829-841
Anti‐CD47 antibody treatment attenuates liver inflammation and fibrosis in experimental non‐alcoholic steatohepatitis models
Background and Aims With the epidemic burden of obesity and metabolic diseases, nonalcoholic fatty liver disease (NAFLD) including steatohepatitis (NASH) has become the most common chronic liver disease in the western world. NASH may progress to cirrhosis and hepatocellular carcinoma. Currently no treatment is available for NASH. Therefore, finding a therapy for NAFLD/NASH is in urgent need. Previously we have demonstrated that mice lacking CD47 or its ligand thrombospondin1 (TSP1) are protected from obesity-associated NALFD. This suggests that CD47 blockade might be a novel treatment for obesity-associated metabolic disease. Thus, in this study, the therapeutic potential of an anti-CD47 antibody in NAFLD progression was determined. Methods Both diet-induced NASH mouse model and human NASH organoid model were utilized in this study. NASH was induced in mice by feeding with diet enriched with fat, fructose and cholesterol (AMLN diet) for 20 weeks and then treated with anti-CD47 antibody or control IgG for 4 weeks. Body weight, body composition and liver phenotype were analyzed. Results We found that anti-CD47 antibody treatment did not affect mice body weight, fat mass, or liver steatosis. However, liver immune cell infiltration, inflammation and fibrosis were significantly reduced by anti-CD47 antibody treatment. In vitro data further showed that CD47 blockade prevented hepatic stellate cell activation and NASH progression in a human NASH organoid model. Conclusion Collectively, these data suggest that anti-CD47 antibody might be a new therapeutic option for obesity-associated NASH and liver fibrosis.
- 15 February 2022
- Published by Wiley in Liver International
- Vol. 42 (4) , 829-841
Anti‐CD47 antibody treatment attenuates liver inflammation and fibrosis in experimental non‐alcoholic steatohepatitis models
Background and Aims With the epidemic burden of obesity and metabolic diseases, nonalcoholic fatty liver disease (NAFLD) including steatohepatitis (NASH) has become the most common chronic liver disease in the western world. NASH may progress to cirrhosis and hepatocellular carcinoma. Currently no treatment is available for NASH. Therefore, finding a therapy for NAFLD/NASH is in urgent need. Previously we have demonstrated that mice lacking CD47 or its ligand thrombospondin1 (TSP1) are protected from obesity-associated NALFD. This suggests that CD47 blockade might be a novel treatment for obesity-associated metabolic disease. Thus, in this study, the therapeutic potential of an anti-CD47 antibody in NAFLD progression was determined. Methods Both diet-induced NASH mouse model and human NASH organoid model were utilized in this study. NASH was induced in mice by feeding with diet enriched with fat, fructose and cholesterol (AMLN diet) for 20 weeks and then treated with anti-CD47 antibody or control IgG for 4 weeks. Body weight, body composition and liver phenotype were analyzed. Results We found that anti-CD47 antibody treatment did not affect mice body weight, fat mass, or liver steatosis. However, liver immune cell infiltration, inflammation and fibrosis were significantly reduced by anti-CD47 antibody treatment. In vitro data further showed that CD47 blockade prevented hepatic stellate cell activation and NASH progression in a human NASH organoid model. Conclusion Collectively, these data suggest that anti-CD47 antibody might be a new therapeutic option for obesity-associated NASH and liver fibrosis.
- 24 August 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 575, 14-19
Absence of CD47 maintains brown fat thermogenic capacity and protects mice from aging-related obesity and metabolic disorder
- 24 August 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 575, 14-19
Absence of CD47 maintains brown fat thermogenic capacity and protects mice from aging-related obesity and metabolic disorder
- Open Access
- 1 February 2021
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 14, 443-454
A Non-Invasive Prediction Model for Non-Alcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Based on the Population of Northern Urumqi, China
Background: High prevalence of non-alcoholic fatty liver disease (NAFLD) occurs in type 2 diabetes mellitus (T2DM), and about 13% of diabetic patients eventually die of liver cirrhosis or liver cancer. The purpose of our research was to develop a non-invasive predictive model of NAFLD in adults with T2DM. Patients and Methods: Adult patients diagnosed with T2DM during physical examination in 2018 in Urumqi were recruited, in total 40,921 cases. We chose questionnaire and physical measurement variables to build a simple, low-cost model. Variables were selected by the least absolute shrinkage and selection operator regression (LASSO). The features chosen by LASSO were used to build the nomogram prediction model of NAFLD. The receiver operating curve (ROC) and calibration were used for model validation. Results: Determinants in the nomogram included age, ethnicity, sex, exercise, smoking, dietary ratio, heart rate, systolic blood pressure (SBP), BMI, waist circumference, and atherosclerotic vascular disease (ASCVD). The area under ROC of developing group and validation group was 0.756 (95% confidence interval 0.750– 0.761) and 0.755 (95% confidence interval 0.746– 0.763), respectively, and the P values of the two calibration curves were 0.694 and 0.950, suggesting that the nomogram had good disease recognition ability and calibration. Conclusion: A nomogram constructed with accuracy can calculate the possibility of NAFLD in adults with T2DM. If validated externally, this tool could be utilized as a non-invasive method to diagnose non-alcoholic fatty liver in adults with T2DM.
- 1 February 2021
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 14, 443-454
Open AccessA Non-Invasive Prediction Model for Non-Alcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Based on the Population of Northern Urumqi, China
Background: High prevalence of non-alcoholic fatty liver disease (NAFLD) occurs in type 2 diabetes mellitus (T2DM), and about 13% of diabetic patients eventually die of liver cirrhosis or liver cancer. The purpose of our research was to develop a non-invasive predictive model of NAFLD in adults with T2DM. Patients and Methods: Adult patients diagnosed with T2DM during physical examination in 2018 in Urumqi were recruited, in total 40,921 cases. We chose questionnaire and physical measurement variables to build a simple, low-cost model. Variables were selected by the least absolute shrinkage and selection operator regression (LASSO). The features chosen by LASSO were used to build the nomogram prediction model of NAFLD. The receiver operating curve (ROC) and calibration were used for model validation. Results: Determinants in the nomogram included age, ethnicity, sex, exercise, smoking, dietary ratio, heart rate, systolic blood pressure (SBP), BMI, waist circumference, and atherosclerotic vascular disease (ASCVD). The area under ROC of developing group and validation group was 0.756 (95% confidence interval 0.750– 0.761) and 0.755 (95% confidence interval 0.746– 0.763), respectively, and the P values of the two calibration curves were 0.694 and 0.950, suggesting that the nomogram had good disease recognition ability and calibration. Conclusion: A nomogram constructed with accuracy can calculate the possibility of NAFLD in adults with T2DM. If validated externally, this tool could be utilized as a non-invasive method to diagnose non-alcoholic fatty liver in adults with T2DM.